New study supports use of PCA3-based test for prostate cancer diagnosis - European commercialization in progress

    Ticker Symbol: CUR

    QUEBEC CITY, March 19 /CNW Telbec/ - New clinical data from a study of
570 men published in the peer-reviewed Journal of Urology (179:15871592, 2008)
supports the use of a PCA3-based test as a tool for diagnosing prostate
cancer. The new study confirms that PCA3, DiagnoCure's highly specific
prostate cancer marker, and the world's first gene-based urine test to help
detect prostate cancer, can provide clinicians with valuable information that
helps guide diagnosis.
    The PCA3 test addresses some of the limitations of existing diagnostic
tools. For example, Prostate Specific Antigen (PSA) is commonly elevated for
reasons not related to prostate cancer, and as a result, PSA testing produces
many "false positive" results, which can burden patients and the healthcare
system. In contrast, the molecular marker PCA3 is elevated only in cancerous
prostate tissue, making it a more specific indicator of cancer than PSA, and
potentially reducing the number of unnecessary biopsies.
    The study also confirms that the PCA3 score correlates with the
probability of positive biopsy. In the study, men with a PCA3 score of less
than five showed a positive biopsy rate of 14 percent; however, a PCA3 score
greater than 100 showed a 69 percent biopsy positive rate.
    "This study is one more piece of evidence that PCA3 is truly an accurate
marker for prostate cancer", said John Schafer, President and CEO of
DiagnoCure. "The compelling results should support the adoption of the test by
physicians who are in need of better tools to help their patients facing
prostate cancer questions."
    The release of this study coincides with significant commercialization
progress made on PCA3 in Europe. In December, Gen-Probe, to which DiagnoCure
granted worldwide diagnostic rights to PCA3 in 2003, announced that they were
increasing their sales and marketing team in the region. More recently, the
Broomfield Hospital in Chelmsford, U.K., began to offer the PCA3 test to their
patients, with the National Health Service assuming the cost through their
local trust.
    The PCA3 test in now available across the European Union and from five
laboratories in the United-States that offer a PCA3-based test using analyst
specific reagents manufactured by Gen-Probe. Also, one additional Canadian
medical laboratory announced earlier this month that they would be offering
the PCA3 test.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC
Colorectal Cancer Staging Test, the first GCC-based molecular test for the
management of colorectal cancer. In 2003, the Company entered into a strategic
alliance with Gen-Probe (NASDAQ:   GPRO) for the development and
commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary molecular marker highly specific to prostate cancer. The test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA(TM)
PCA3 in vitro assay. In addition to its own research, the Company intends to
acquire or in-license additional promising cancer biomarkers from both
academic and commercial institutions. For more information, visit

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF

For further information:

For further information: Investors: J.F. Bureau, CFA, Sr. Vice President
and CFO, DiagnoCure Inc., (418) 527-6100,;
Media: Jean-Pierre Trudel, Jean-Pierre Trudel & Associates, (514) 347-6111,

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890